Skip to main content
Equibles
CPIX logo

CPIX · Cumberland Pharmaceuticals Inc · Metrics

Track CPIX — free

Use CPIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CPIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.48 +0.31 (+3.79%) At close · Oct 22
Rebalance outlook locked
Market Cap
$127.06M
Shares
14.98M
Volume · Oct 22 39.18K Avg daily vol (3M) 75.32K

CPIX metrics

94 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.48
Market cap
$127.06M

Price action

20 metrics
Price change (1W)
+12.5%
Price change (30D)
+3.4%
Price change (3M)
+21.3%
Price change (6M)
+117.4%
Price change (YTD)
+113.1%
Price change (1Y)
+145.1%
Trailing year
Price change (5Y)
+216.4%
52-week high
$8.97
52-week low
$1.90
Change from 52-week high
-5.5%
Change from 52-week low
+346.3%
Annualized volatility
89.3%
Annualized volatility (3M)
79.1%
Beta
0.9
RSI (14D)
63.7
Price vs SMA 50
+14.4%
Price vs SMA 200
+54.0%
Avg volume (3M)
75,322
Relative volume
0.5
Average dollar volume
$558,090

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
14.98M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.7×
reciprocal yield 27.0%
EV / EBITDA
105.4×
reciprocal yield 0.9%
EV / EBIT
—
P / sales
4.1×
reciprocal yield 24.6%
P / book
7.3
reciprocal yield 13.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.1%
P / FCF
—
P / operating cash flow
170.3
reciprocal yield 0.6%
Earnings yield
-8.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.8×
reciprocal yield 128.8%
EV / revenue historical average (5Y)
0.8×
reciprocal yield 124.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
30.9×
reciprocal yield 3.2%
EV / EBITDA historical average (5Y)
30.9×
reciprocal yield 3.2%

Dividends & buybacks

7 metrics
Dividend yield
17.7%
Trailing 12 months
Payout ratio
—
Shareholder yield
0.1%
Dividend / share (TTM)
$1.50
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2026-08-03

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
85.0%
Operating margin
-30.8%
Trailing 12 months
Net margin
-34.9%
Gross profit (TTM)
$24.31M
Operating profit (TTM)
−$9.63M
Net income (TTM)
−$10.92M
Trailing 12 months
Diluted EPS (TTM)
$-0.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.14
Gross profit per diluted share (TTM)
$1.66
Operating profit per diluted share (TTM)
$-0.65
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.73
Operating cash flow per diluted share (TTM)
$0.05
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.39
Stock compensation per diluted share (TTM)
$0.03
Book value per share
$1.66

Growth

11 metrics
Revenue growth YoY
-56.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.27M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.1%
Year over year · more shares
Revenue CAGR (3Y)
+2.0%
Revenue CAGR (5Y)
+3.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-16.7%
FCF CAGR (5Y)
-1.7%

Quality

14 metrics
Return on equity
-62.6%
Return on assets
-17.4%
Debt / equity
0.0
Current ratio
1.0
EBITDA (TTM)
$1.10M
Free cash flow (TTM)
—
Quick ratio
1.0
Interest coverage
-23.0
Net debt / EBITDA
-10.4
Return on invested capital
—
Trailing 12 months
Net cash
$11.44M
Latest balance sheet
Cash & equivalents
$3.86M
Total assets
$62.88M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$745,969
Capital expenditures (TTM)
$62,070
R&D (TTM)
$5.66M
SG&A (TTM)
—
Stock compensation (TTM)
$438,130
R&D / revenue
18.1%
Stock compensation / revenue
1.4%

Ownership (13F)

9 metrics
13F filers
33
13F filer change QoQ
+3
Institutional ownership
18.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
11.4%
Private-fund adviser ownership
10.8%
Active holders' share change QoQ
-15.7%
Holder tenure
12.6
Price vs estimated holder cost
+64.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.3%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 7.5 days to cover
Days to cover
7.5d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1087294 CUSIP 230770109 13F (30d) 2 filings 2 filers Visit website Investor relations